Ribociclib - National Cancer Institute

Ribociclib - National Cancer Institute

Ribociclib

• 
• 
• 
• 
• 
• 
• 

(RY-boh-SY-klib)

This page contains brief information about ribociclib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Kisqali

FDA Approved

Yes

FDA Approval for Ribociclib

Use in Cancer

Ribociclib is approved to be used with an aromatase inhibitor to treat:

• Breast cancer that is hormone receptor positive (HR+) and HER2 negative(HER2-) and is advanced or has metastasized (spread to other parts of the body). It is used in postmenopausal women who have not been treated with hormone therapy.

Ribociclib is also being studied in the treatment of other types of cancer.

More About Ribociclib

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Ribociclib Improves Progression-Free Survival for Some Women with Metastatic Breast Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Ribociclib - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.

• Posted: March 16, 2017